BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 22393773)

  • 21. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PIM activity in tumours: A key node of therapy resistance.
    Rebello RJ; Huglo AV; Furic L
    Adv Biol Regul; 2018 Jan; 67():163-169. PubMed ID: 29111105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.
    Rout AK; Dehury B; Parida SN; Rout SS; Jena R; Kaushik N; Kaushik NK; Pradhan SK; Sahoo CR; Singh AK; Arya M; Behera BK
    Int J Biol Macromol; 2024 Jun; 270(Pt 1):132030. PubMed ID: 38704069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
    Pogacic V; Bullock AN; Fedorov O; Filippakopoulos P; Gasser C; Biondi A; Meyer-Monard S; Knapp S; Schwaller J
    Cancer Res; 2007 Jul; 67(14):6916-24. PubMed ID: 17638903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
    Kreuz S; Holmes KB; Tooze RM; Lefevre PF
    Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pim kinase-dependent inhibition of c-Myc degradation.
    Zhang Y; Wang Z; Li X; Magnuson NS
    Oncogene; 2008 Aug; 27(35):4809-19. PubMed ID: 18438430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation.
    Zippo A; De Robertis A; Serafini R; Oliviero S
    Nat Cell Biol; 2007 Aug; 9(8):932-44. PubMed ID: 17643117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
    Jeyapal GP; Chandrasekar MJN; Krishnasamy R; Selvaraj J; Mohammad M; Nanjan MJ
    Anticancer Agents Med Chem; 2018; 18(8):1100-1114. PubMed ID: 29384063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death.
    Pircher TJ; Zhao S; Geiger JN; Joneja B; Wojchowski DM
    Oncogene; 2000 Jul; 19(32):3684-92. PubMed ID: 10951575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
    Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
    Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.
    Martín-Sánchez E; Odqvist L; Rodríguez-Pinilla SM; Sánchez-Beato M; Roncador G; Domínguez-González B; Blanco-Aparicio C; García Collazo AM; Cantalapiedra EG; Fernández JP; Curiel del Olmo S; Pisonero H; Madureira R; Almaraz C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; Real FX; García JF; Bischoff JR; Piris MA
    PLoS One; 2014; 9(11):e112148. PubMed ID: 25386922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.
    Shah N; Pang B; Yeoh KG; Thorn S; Chen CS; Lilly MB; Salto-Tellez M
    Eur J Cancer; 2008 Oct; 44(15):2144-51. PubMed ID: 18715779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.
    Isaac M; Siu A; Jongstra J
    Drug Resist Updat; 2011; 14(4-5):203-11. PubMed ID: 21601509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Pim kinases: new targets for drug development.
    Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
    Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
    Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
    Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
    Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL
    J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
    Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
    ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pim-1 regulates cardiomyocyte survival downstream of Akt.
    Muraski JA; Rota M; Misao Y; Fransioli J; Cottage C; Gude N; Esposito G; Delucchi F; Arcarese M; Alvarez R; Siddiqi S; Emmanuel GN; Wu W; Fischer K; Martindale JJ; Glembotski CC; Leri A; Kajstura J; Magnuson N; Berns A; Beretta RM; Houser SR; Schaefer EM; Anversa P; Sussman MA
    Nat Med; 2007 Dec; 13(12):1467-75. PubMed ID: 18037896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.